Lab plans to raise $32.2 million

FORT MYERS — NeoGenomics says it plans to sell 7 million shares in a secondary offering to raise $32.2 million to fund its growth, the company says in securities filings.

NeoGenomics says it could raise as much as $37 million if underwriters exercise their option to buy more shares. Underwriters include William Blair, Craig-Hallum Capital Group, Stephens Inc., Roth Capital Partners and Sidoti & Co.

The additional shares will be sold for $4.60 per share. After the successful completion of the offering, NeoGenomics will have about 57 million shares outstanding, 58 million if underwriters exercise their option to purchase additional shares. The company's shares are traded on Nasdaq (symbol: NEO).

“We intend to use the net proceeds for working capital, capital expenditures and other corporate purposes, including potential acquisitions,” NeoGenomics says in a securities filing. “The company may also use proceeds to repay debt, although at this time no decision has been made to the amount or timing of repayment.”

The cancer-testing firm is headquartered in Fort Myers and operates labs in Tampa and in California and Tennessee.